clinical trial · NCT07499362
Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany·phase2·recruiting·n = 20
Tenosynovial Giant Cell TumorPimicotinib
brief summary
The primary purpose of this study is to assess the tolerability, pharmacokinetics, and efficacy of pimicotinib in Japanese participants with TGCT
started
Mar 26, 2026
primary completion
Nov 22, 2029
completion
Nov 22, 2029
last updated
Jun 16, 2026
detailed description
The purpose of this study is to assess the tolerability, pharmacokinetics (PK), efficacy, and safety of pimicotinib in Japanese participants with TGCT in two cohorts: Safety Run-in and Expansion.
official title
Phase 2, Single-arm Study to Investigate the Tolerability, Pharmacokinetics, Efficacy, and Safety of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol